What should we do about vaccination of patients on anti-CD20 antibody therapy?

The SARS-CoV-2 antibody response was decreased in patients with multiple sclerosis (MS) who were infected with COVID-19 and received anti-CD20 therapy

Vaccination efforts for COVID-19 are currently underway worldwide. At present, there is insufficient evidence of the vaccine’s efficacy and safety in patients with neurological diseases, such as stroke, dementia and intractable neurological diseases. Despite the fact that many patients with neurological diseases are elderly and often have systemic complications, I believe that neurologists should nonetheless actively recommend vaccination to their patients. However, there are at least three problems that I encounter in my daily clinical practice when I vaccinate patients with neurological diseases.

The first problem is that many patients with dementia have no family members or other relatives, and self-determination for vaccination is difficult. The second problem is that patients with amyotrophic lateral sclerosis or muscular dystrophy have significant muscle atrophy; thus, it is difficult for them to receive…

Read article at journal's website

Related Articles


Your email address will not be published. Required fields are marked *